The short answer: Start with the state board of pharmacy where the pharmacy is located, then check any board in a state it ships into, since out-of-state pharmacies may need a nonresident license. If it calls itself a 503B outsourcing facility, check FDA’s registered list. FDA inspection and warning-letter records add context, but none is a complete report card.
Why check a compounding pharmacy’s license at all?
Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before marketing [1]. FDA also notes that people who get compounded drugs through online pharmacies or telehealth may not know which compounder made the drug, including whether it is appropriately licensed and regulated, for example by state authorities [1]. A license lookup helps close that gap. For the two federal lanes, see our explainer, 503A vs 503B Pharmacies: What the Difference Means for Patients.
What do you need before you start?
Gather the pharmacy’s legal name and any “doing business as” (dba) name, street address and state, a license number if printed on the label or paperwork, and whether it calls itself 503A or 503B. If you don’t know which pharmacy fills your prescription, ask your provider. FDA says to fill prescriptions at a state-licensed pharmacy [2].
How do you look up a state license?
There is no single national license lookup. The National Association of Boards of Pharmacy (NABP) keeps a directory with a phone number and website link for each state board [3]; the board’s own database is the primary source. In general:
- Open the state board’s search from the NABP directory [3].
- Pick the license type (for example pharmacy, sterile compounding, or outsourcing facility).
- Search by name or license number. California’s page advises entering one or the other, not both [4].
- Read the status, expiration date, and any disciplinary flag, and note the date you checked.
Two examples, limited to what each page states:
- California: the Board of Pharmacy’s “Verify a License” page lists license types including Pharmacies, Sterile Compounding, Non-Resident Sterile Compounding, Outsourcing Facility, and Nonresident Outsourcing Facility. “Yes” in the Actions column means disciplinary information is on record [4].
- Washington: the Department of Health says its search data comes from its database and is updated daily. Provider and facility searches are separate, so a pharmacy is found through the facility search [5].
What is the difference between resident and nonresident licensure, and why does it matter?
A “resident” pharmacy is licensed where it is located. A “nonresident” pharmacy ships into other states and may need a license in each destination state. Two examples:
- California: a nonresident pharmacy shipping compounded sterile drugs in must hold a nonresident pharmacy license and a separate nonresident sterile compounding license [6].
- Washington: an out-of-state pharmacy that ships, mails, or delivers drugs into the state needs a nonresident pharmacy license [7].
Rules vary, so check the destination state’s board. Our State-by-State Guide to Compounded GLP-1 Rules is coming soon and will cover more.
How do you check FDA’s list of registered 503B outsourcing facilities?
FDA’s Registered Outsourcing Facilities table carries an “Updated as of” date (9/30/2026 when we checked) [8], so note the date when you use it. A listing shows registration dates, last inspection date, whether a Form FDA 483 was issued, and the action based on that inspection [8]. Three limits:
- A listing means registration information was complete; it is not FDA approval of any product [1][8].
- A Form 483 is not a final agency determination, and the table omits state board actions [8].
- FDA’s list covers only registered 503B outsourcing facilities [8]; a 503A pharmacy would not appear on it.
How do you look up FDA inspection and warning letter records?
Three tools exist; none is comprehensive:
- FDA’s “Compounding: Inspections, Recalls, and other Actions” page has A–Z firm listings of 483s, warning letters, and other actions, and suggests searching the Warning Letter Database for “telehealth” [9].
- FDA’s Warning Letters database can be browsed by company, date, and subject, with columns for response and closeout letters [10].
- FDA’s Inspection Classification Database and Data Dashboard show final classifications (NAI, VAI, and OAI, FDA’s classification codes). They exclude state inspections, are not a comprehensive listing, and show only final actions [11].
A warning letter is a notice of documented violations, not a final determination. FDA says later contact may have changed the status of matters in a letter [10], so look for a response or closeout letter. Our planned How to Read an FDA Warning Letter (and What It Doesn’t Mean) is coming soon and goes deeper.
What does “not found” mean, and what doesn’t it mean?
Benign reasons include a different legal name or dba, the wrong state or license type, a license held by an affiliated entity, a typo, or lookup lag. Washington, for instance, lists 503B outsourcing facilities under its wholesaler category, not as pharmacies [7]. On FDA’s list, the pharmacy may simply be 503A [8].
“Not found” does not prove wrongdoing. “Found” does not prove quality: a license shows legal status when you checked, not product quality [1]. Next steps: recheck spelling and dba names, call the state board (numbers are in the NABP directory [3]), and ask the provider.
What questions can you ask your provider or the pharmacy?
- Which pharmacy compounds this, and what are its legal name and license number?
- Which state(s) is it licensed in, including mine if it ships here?
- Is it 503A or 503B, and if 503B, is it on FDA’s list?
- Has it received an FDA warning letter or state board action, and with what outcome?
- How do I report a problem?
Worth a follow-up question: no name or license information on request, reluctance to say which pharmacy fills the order, or “FDA-approved” used to describe a compounded product. FDA also lists, among its consumer red flags, a claim that a compounded drug is “the same as” an FDA-approved one [2]. Each is a prompt to ask, not proof of a problem.
How does this connect to the compounded GLP-1 story?
Much attention on compounded GLP-1 drugs involves online and telehealth channels, where FDA advises using a state-licensed pharmacy [2]. For the timeline, see The Shortage Era, 2022-2026: A Timeline of Compounded GLP-1 Rules (coming soon).
Where to look, at a glance
| Source | What it answers | What it doesn’t |
|---|---|---|
| State board license search | License type, status, and a disciplinary flag where offered [4][5] | Other states’ licenses |
| NABP Boards of Pharmacy directory | Board websites and phone numbers [3] | It points to boards; the board’s database is the primary source [3][4] |
| FDA Registered Outsourcing Facilities | 503B registration, last inspection, 483 issued, action taken [8] | State board actions [8] |
| FDA Compounding: Inspections, Recalls, and other Actions | 483s, warning letters, other actions by firm [9] | Final agency determinations; a 483 lists observations and is not one [12] |
| FDA Warning Letters database | Letters by company, date, subject; response and closeout letters [10] | Current status; it may have changed after the letter [10] |
| FDA Inspection Classification Database | Final classifications (NAI, VAI, OAI) [11] | State inspections; it is not comprehensive [11] |
Frequently asked questions
Is there one national database of pharmacy licenses?
No. NABP’s directory links to each state board, and the state board’s database is the primary source [3].
If a pharmacy is licensed in another state, can it ship to me?
It depends on your state’s nonresident requirements; California and Washington each have them [6][7]. Check your state board [3].
Does being on FDA’s outsourcing facility list mean the drugs are FDA-approved?
No [1][8].
What does a Form FDA 483 mean?
It lists observations an investigator believes may constitute violations. It does not constitute a final agency determination [12].
Where do I report a problem with a compounded medication?
FDA’s MedWatch program takes reports of serious reactions and product quality problems online or on Form 3500/3500B [13]. You can also contact your state board [3].
Sources
All sources accessed 2026-09-30. Regulatory status described as of September 2026.
- U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers (accessed 2026-09-30)
- U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (accessed 2026-09-30)
- NABP. “Boards of Pharmacy.” https://nabp.pharmacy/about/boards-of-pharmacy/ (accessed 2026-09-30)
- California State Board of Pharmacy. “Verify a License (License Search).” https://www.pharmacy.ca.gov/about/verify_lic.shtml (accessed 2026-09-30)
- Washington State Department of Health. “Provider Credential or Facility Search.” https://doh.wa.gov/licenses-permits-and-certificates/provider-credential-or-facility-search (accessed 2026-09-30)
- California State Board of Pharmacy. “Sterile Compounding/Nonresident Sterile Compounding/Hospital In-Patient Sterile Compounding Pharmacy License.” https://www.pharmacy.ca.gov/applicants/sicp.shtml (accessed 2026-09-30)
- Washington State Department of Health. “Pharmacies and Pharmaceutical Firms: Licensing Information.” https://doh.wa.gov/licenses-permits-and-certificates/facilities-z/pharmacies-and-pharmaceutical-firms/licensing-information (accessed 2026-09-30)
- U.S. Food and Drug Administration. “Registered Outsourcing Facilities” (page stamped “Updated as of 9/30/2026” when accessed). https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities (accessed 2026-09-30)
- U.S. Food and Drug Administration. “Compounding: Inspections, Recalls, and other Actions.” https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions (accessed 2026-09-30)
- U.S. Food and Drug Administration. “Warning Letters.” https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters (accessed 2026-09-30)
- U.S. Food and Drug Administration. “Inspection Classification Database”; FDA Data Dashboard. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-classification-database ; https://datadashboard.fda.gov/oii/cd/inspections.htm (accessed 2026-09-30)
- U.S. Food and Drug Administration. “Understanding the Form FDA 483 Process and Timeline.” https://www.fda.gov/media/162162/download (accessed 2026-09-30)
- U.S. Food and Drug Administration. “MedWatch: Reporting Serious Problems to FDA.” https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/reporting-serious-problems-fda (accessed 2026-09-30)
Educational content only; not medical or legal advice. Compound Chronicle is an educational publisher, not a pharmacy or clinic. Jules Whitaker is an editorial pen name; this article was researched with AI assistance and goes through Compound Chronicle’s editorial review.
We may have a financial affiliation with some entities featured on this page.